global
need
elucid
protect
antigen
express
sarscoronaviru
sarscov
monoclon
antibodi
reagent
recognis
specif
antigen
sarscov
need
urgent
report
develop
immunochem
characteris
panel
murin
monoclon
antibodi
mab
sarscov
present
base
upon
specif
bind
requir
biolog
activ
initi
screen
elisa
use
highli
purifi
viru
coat
antigen
result
select
mab
sar
viru
subsequ
screen
step
reduc
panel
seventeen
igg
mab
singl
mab
specif
nucleoprotein
seen
western
immunoblot
five
mab
react
spike
protein
two
spikespecif
mab
demonstr
abil
neutralis
sarscov
vitro
anoth
four
western
immunoblotneg
mab
also
neutralis
viru
util
mab
diagnost
develop
demonstr
antibodi
convalesc
sar
patient
normal
human
serum
also
shown
specif
compet
bind
mab
whole
sarscov
studi
highlight
import
use
standardis
assay
reagent
mab
use
develop
diagnost
test
studi
sarscov
pathogenesi
vaccin
develop
sarscoronaviru
sarscov
recognis
causal
agent
sever
acut
respiratori
syndrom
sar
human
viru
caus
nearli
death
infect
peopl
variou
affect
countri
throughout
world
stadler
et
al
sarscoronaviru
spike
protein
pairwis
ident
amino
acid
level
spike
protein
previous
characteris
coronavirus
recent
genom
sarscov
isol
implic
toronto
outbreak
sequenc
entireti
marra
et
al
rota
et
al
product
mab
sarscov
viru
critic
diagnost
develop
vaccin
research
studi
viral
pathogenesi
assay
detect
presenc
viral
encod
protein
nucleic
acid
may
prefer
diagnosi
sar
infect
develop
serum
antibodi
infect
individu
quit
protract
li
et
al
coronavirus
envelop
singlestrand
rna
virus
replic
host
cell
cytoplasm
field
et
al
coronavirus
form
singl
genu
famili
coronavirida
virion
larg
nm
diamet
pleomorph
gener
spheric
particl
virion
coronavirus
contain
three
major
protein
phosphoryl
nucleocapsid
protein
n
small
membraneembed
glycoprotein
larg
clubshap
peplom
glycoprotein
appear
em
micrograph
protrud
spike
nm
length
protein
synthesis
ribosom
bound
endoplasm
reticulum
accumul
golgi
apparatu
subcellular
localis
protein
golgi
believ
influenc
site
viru
bud
infect
cell
sprotein
mediat
mani
biolog
properti
viru
includ
attach
cell
receptor
penetr
cellfus
major
target
virusneutralis
antibodi
collin
et
al
talbot
et
al
wege
et
al
jimenez
et
al
laud
et
al
godet
et
al
portion
glycoprotein
incorpor
bud
virion
transport
plasma
membran
cell
remain
bound
cell
surfac
gerna
et
al
coronavirus
infect
wide
rang
mammalian
host
produc
varieti
diseas
outcom
includ
respiratori
diseas
enter
enceph
antigen
similar
variou
coronavirus
demonstr
resid
sprotein
use
studi
evolut
viru
famili
brian
et
al
coronavirus
caus
enter
respiratori
diseas
pathophysiolog
event
lead
clinic
symptom
due
acut
cytocid
infect
target
cell
infect
limit
local
immun
respons
result
product
secretori
antibodi
specif
sprotein
enjuan
et
al
contrast
mani
coronavirus
maintain
spread
popul
inappar
subclin
infect
sequenc
event
lead
chronic
versu
acut
diseas
unknown
like
depend
express
viral
gene
function
impair
host
cell
interact
host
immun
respons
critic
need
elucid
immunolog
basi
protect
sarscov
infect
recent
sar
sprotein
shown
function
fusogen
kda
size
xiao
et
al
host
cell
receptor
angiotensinconvert
enzym
recent
identifi
function
receptor
sarscov
mediat
infect
cell
vitro
li
et
al
therefor
antibodi
respons
sprotein
may
neutralis
infect
sarscov
immunogenet
antibodi
respons
protect
epitop
particular
import
lead
clearer
understand
natur
protect
antibodi
respons
sar
lastli
product
protect
monoclon
antibodi
may
lead
develop
new
recombin
therapeut
antibodi
order
provid
rapid
protect
sar
patient
present
work
descript
develop
murin
mab
sarscov
involv
toronto
sar
outbreak
present
mab
analys
pertin
immunochem
properti
abil
neutralis
sarscov
vitro
prepar
partial
purifi
wholeviru
antigen
sarscov
expand
plaqu
purif
cell
monolay
partial
purifi
sucros
cushion
highli
purifi
sarscov
strain
isol
patient
infect
toronto
sar
outbreak
krokhin
et
al
prepar
way
except
viral
particl
purifi
use
gradient
centrifug
briefli
ml
supernat
sarscov
infect
cell
concentr
first
top
cushion
iodixanol
beckman
rotor
mississauga
viru
subsequ
mix
form
suspens
iodixanol
subject
centrifug
beckman
nvt
rotor
mississauga
h
g
fraction
collect
bottom
selfgener
gradient
test
western
immunoblot
sarscovinfect
convalesc
human
patient
serum
sarscov
posit
fraction
pool
dialys
phosphat
buffer
salin
pb
dialys
viru
prepar
concentr
ultracentifug
h
g
immunis
mice
perform
accord
ncfad
standard
oper
procedur
fiveto
sixweekold
femal
balbc
mice
charl
river
wilmington
inject
subcutan
sc
g
betapropiolactoneinactiv
partial
purifi
sarscov
strain
equal
part
complet
freund
adjuv
cfa
difco
bd
oakvil
day
day
mice
receiv
g
partial
purifi
sarscov
sc
incomplet
freund
adjuv
ifa
total
volum
l
day
mice
receiv
g
antigen
total
volum
l
sc
ifa
mice
receiv
final
booster
inject
g
highli
purifi
sarscov
l
pb
intraperiton
caviti
day
prior
hybridoma
fusion
mice
euthanis
anaesthesia
overdos
exsanguin
cardiac
punctur
spleen
subsequ
excis
asept
condit
infect
vero
cell
scrape
cm
corn
tissu
cultur
flask
corn
ny
clarifi
centrifug
borat
salin
mixtur
boric
acid
nacl
naoh
use
wash
cell
pellet
twice
pellet
resuspend
ml
borat
salin
triton
flask
pellet
kept
c
use
water
bath
sonic
ten
minut
power
debri
pellet
via
centrifug
g
min
supernat
collect
store
c
aliquot
later
use
remov
mous
spleen
prepar
spleen
myeloma
cell
fusion
hybridoma
product
perform
accord
ncfad
standard
oper
procedur
ampoul
myeloma
cell
line
atcc
rockvil
md
thaw
week
prior
fusion
grown
bd
cell
mab
quantum
yield
medium
presenc
sigma
oakvil
cell
logphas
growth
time
fusion
hybridoma
fusion
perform
essenti
origin
describ
kohler
milstein
follow
modif
briefli
spleen
harvest
day
final
boost
given
antigen
splenocyt
prepar
splenic
perfus
follow
asept
condit
spleen
perfor
cm
syring
gaug
steril
dispos
needl
spleen
cell
perfus
spleen
inject
serum
free
bd
cell
mab
quantum
yield
medium
bdpharmingen
oakvil
two
ident
immunis
mous
spleen
use
produc
hybridoma
clone
fusion
perform
use
myeloma
line
logphas
growth
ml
roch
basel
sw
ad
dropwis
min
gentli
tap
tube
contain
thoroughli
wash
myelomasplenocyt
pellet
peg
slowli
dilut
three
minut
serum
free
bdcell
mab
quantum
yield
medium
cell
resuspend
mix
ml
stemcel
clonacel
medium
hat
vancouv
bc
contain
ml
origen
hybridoma
clone
factor
hcf
igen
gaithersburg
md
plate
accord
manufactur
instruct
plate
incub
c
co
overlay
day
humidifi
chamber
visibl
coloni
pick
plate
approxim
week
growth
place
plate
contain
l
complet
hybridoma
medium
supplement
hypoxanthin
thymidin
sigma
oakvil
hcf
fb
wisent
supernat
screen
day
later
via
elisa
use
purifi
viru
antigen
isotyp
perform
use
commerci
murin
isotyp
dipstick
test
roch
basel
sw
accord
manufactur
instruct
hybridoma
cultur
supernat
concentr
fold
use
amicon
stir
cell
nitrogen
concentr
kda
cutoff
millipor
membran
millipor
billerica
hybridoma
cultur
supernat
assay
bind
highli
purifi
sarscov
elisa
assay
cultur
cell
confluent
cultur
plate
costar
well
elisa
plate
corn
ny
coat
either
bovin
serum
albumin
bsa
highli
purifi
sarscov
ngwell
pb
overnight
c
block
bsa
pb
h
c
supernat
lwell
incub
neat
h
c
elisa
plate
wash
time
distil
water
pat
dri
paper
towel
pangoat
antimous
igghrp
antibodi
southern
biotechnolog
associ
birmingham
alabama
dilut
bsa
pb
appli
elisa
plate
min
c
wash
describ
posit
bind
detect
commerci
abt
use
accord
manufactur
instruct
roch
basel
sw
od
read
nm
min
interv
addit
develop
reagent
mous
immun
preimmun
sera
dilut
bsa
pb
use
posit
neg
control
respect
establish
hybridoma
screen
assay
competit
elisa
celisa
measur
bind
murin
mab
highli
purifi
sarscov
presenc
human
serum
infect
serum
confirm
infect
patient
wellestablish
sar
sampl
initi
set
patient
viru
isol
plate
coat
highli
purifi
sarscov
ng
per
well
normal
human
serum
serum
convalesc
sar
patient
serial
dilut
bsapb
allow
react
preblock
plate
min
mab
spike
specif
nucleoprotein
specif
predilut
concentr
give
approxim
halfmaximum
optic
densiti
h
develop
presenc
compet
serum
dilut
mab
prepar
appli
well
incub
develop
celisa
perform
describ
whole
virion
sarscovinfect
vero
cell
lysat
final
total
protein
concentr
g
per
lane
boil
sdsload
buffer
min
sampl
load
criterion
precast
gel
biorad
mississauga
electrophores
v
min
protein
transfer
immobilon
nylon
membran
millipor
billerica
h
room
temperatur
v
overnight
v
c
blot
block
bsa
tb
rins
three
time
tb
react
monoclon
antibodi
overnight
c
antibodi
supernat
react
neat
concentr
supernat
dilut
bsa
pb
blot
wash
three
time
min
incub
secondari
antibodi
tb
bsa
h
blot
wash
develop
use
dab
insolubl
substrat
pierc
rockford
il
monolay
sarsinfect
vero
cell
stain
follow
glass
slide
coat
infect
vero
cell
monolay
fix
aceton
slide
irradi
kilogrey
cobalt
gamma
irradi
remov
biocontain
store
c
dilut
antibodi
test
sera
made
initi
plate
bdfalcon
oakvil
steril
phosphatebuff
salin
ph
sampl
allow
incub
min
c
incub
wash
distil
water
fluorescein
label
goat
antimous
secondari
antibodi
sigma
oakvil
dilut
pb
ad
slide
incub
min
c
wash
air
dri
slide
coat
mount
medium
store
c
examin
immunodotblot
analysi
perform
use
immobilon
nylon
membran
millipor
billerica
total
l
sarscov
antigen
infect
vero
cell
lysat
g
highli
purifi
viru
coat
per
spot
h
c
attempt
characteris
immunochem
properti
individu
mab
antigen
pretreat
sever
differ
condit
follow
untreat
nativ
antigen
denatur
heat
treatment
c
min
denatur
sodium
dodecyl
sulphat
treatment
sd
prior
coat
membran
denatur
heat
treatment
sd
togeth
reduc
betamercaptoethanol
prior
coat
membran
denatur
temperatur
reduc
togeth
denatur
heat
sd
presenc
betamercaptoethanol
antigenco
blot
block
bsa
tb
h
c
rins
three
time
tb
prior
incub
mab
concentr
mab
supernat
dilut
bsa
tb
trisbuff
salin
ph
react
overnight
c
rotari
platform
shaker
gentl
agit
blot
wash
three
time
min
incub
secondari
antibodi
goat
antimous
igghrp
southern
biotech
tb
bsa
h
blot
wash
develop
use
dab
insolubl
substrat
pierc
rockford
il
elisa
posit
monoclon
antibodi
screen
neutralis
sarscov
use
two
independ
format
first
standard
plaqu
reduct
assay
second
measur
reduct
cytopath
effect
cpe
microtit
format
standard
plaqu
reduct
neutralis
test
perform
previous
describ
beati
et
al
use
highli
purifi
sarscov
briefli
mixtur
pretitr
pfu
sarscov
serial
twofold
dilut
hybridoma
supernat
incub
c
h
ad
six
well
plate
contain
vero
cell
monolay
incub
c
h
nutrientagar
overlay
ad
plate
place
co
incub
c
approxim
day
second
overlay
ad
contain
neutral
red
vital
stain
plate
check
period
next
day
plaqu
format
highest
dilut
test
produc
plaqu
reduct
least
defin
titrat
end
point
microtit
format
cpe
reduct
assay
use
test
sarscov
reactiv
mab
neutralis
sarscov
transmiss
gastroenter
viru
diamond
strain
kindli
provid
dr
susi
carman
lsd
univers
guelph
briefli
concentr
hybridoma
supernat
dilut
cell
cultur
medium
incub
either
highli
purifi
sarscov
strain
tgev
h
c
final
dilut
virusantibodi
mix
transfer
onto
cell
monolay
plate
costar
corn
ny
vero
cell
use
sarscov
st
cell
tgev
plate
incub
cpe
develop
viru
back
titrat
control
elisa
screen
highli
purifi
sarscov
identifi
panel
mab
reactiv
sarscov
antigen
prepar
neg
screen
bsa
reduc
number
panel
iggk
type
mab
fig
tabl
gener
bind
reactiv
mab
greatli
affect
conform
puriti
antigen
illustr
decreas
bind
mab
test
elisa
heat
denatur
pure
sarscov
antigen
compar
nativ
viru
fig
clearli
show
import
select
suitabl
antigen
screen
assay
western
immunoblot
analysi
identifi
mab
sarscov
spike
nucleoprotein
five
mab
react
specif
sarscov
spike
protein
western
immunoblot
mab
recognis
spike
western
immunoblot
highli
purifi
viru
infect
cell
lysat
fig
react
mockinfect
cell
lysat
data
shown
result
suggest
mab
target
linear
epitop
within
spike
protein
anoth
mab
bound
fig
elisa
reactiv
mab
whole
inactiv
sarscov
hybridoma
supernat
test
dilut
pb
bsa
preblock
plate
coat
ng
per
well
inactiv
highli
purifi
sarscov
posit
clone
identifi
posit
bind
color
well
least
fourfold
higher
background
level
reactiv
bsa
antigen
legend
black
barsn
highli
purifi
sarscov
white
barsheat
denatur
highli
purifi
sarscov
grey
barsbsa
control
viru
neutralis
test
perform
independ
separ
contain
laboratori
nml
nation
microbiolog
laboratori
ncfad
nation
centr
foreign
anim
diseas
last
six
row
denot
neutralis
clone
b
singl
dilut
test
microwel
format
c
protein
specif
test
shown
determin
western
immunoblot
purifi
viru
infect
cell
lysat
denatur
condit
fig
u
unknown
target
antigen
immunodotblot
perform
use
antigen
treat
variou
condit
describ
section
n
nativ
h
heat
denatur
c
min
sd
treat
hd
heat
presenc
sd
r
treat
reduc
agent
betamercaptoethanol
h
r
heat
presenc
reduc
agent
betamercaptoethanol
treat
heat
sd
reduc
agent
betamercaptoethanol
e
immunefluoresc
whole
cell
slide
infect
sarscov
see
fig
strong
posit
reaction
posit
reaction
weak
posit
reaction
neg
reaction
f
epitop
properti
describ
follow
l
linear
continu
e
surfac
expos
c
conform
p
protect
vitro
nd
determin
nucleoprotein
western
immunoblot
assay
interestingli
major
identifi
mab
bound
spike
protein
nucleoprotein
despit
strong
seroreact
polyclon
serum
immunis
mice
nucleoprotein
fig
ident
target
antigen
eleven
mab
could
determin
western
immunoblot
analysi
observ
suggest
mab
like
target
conform
epitop
sensit
condit
employ
analys
work
plan
identifi
specif
target
mab
immunodotblot
analysi
reveal
spectrum
conform
requir
bind
summaris
tabl
effect
differ
denatur
treatment
bind
activ
subset
neutralis
nonneutralis
mab
examin
use
immunodotblot
assay
infect
lysat
compar
uninfect
lysat
seri
condit
test
includ
exposur
heat
deterg
reduc
agent
combin
thereof
interestingli
mab
bind
nucleoprotein
western
immunoblot
bind
sarscov
antigen
immunodotblot
condit
test
inher
charg
highli
phosphoryl
nucleoprotein
immobilon
membran
use
assay
may
provid
explan
result
immunodot
blot
perform
mab
howev
bind
mab
consid
conform
bind
sarscov
protein
western
immunoblot
fig
bind
spike
protein
specif
mab
inhibit
immunodotblot
assay
antigen
treat
heat
plu
deterg
heat
plu
deterg
plu
reduc
agent
immunodotblot
assay
instead
perform
use
purifi
viru
particl
result
ident
nucleoprotein
specif
mab
spike
specif
mab
data
shown
antigen
pretreat
western
immunoblot
depend
applic
electr
current
differ
compar
passiv
adsorpt
elisa
immunodotblot
assay
clearli
alway
correl
one
anoth
studi
illustr
need
use
multipl
assay
epitop
characteris
reveal
limit
current
epitop
classif
scheme
spike
protein
immunodomin
antigen
inactiv
sarscov
use
antigen
murin
antibodi
respons
inactiv
whole
sarscov
focus
upon
sar
spike
np
protein
shown
specif
recov
mab
multipl
sarscov
protein
appear
target
mous
serum
antibodi
shown
western
blot
fig
immun
sera
major
mab
recognis
spike
protein
western
immunoblot
sarscov
infect
host
immun
system
expos
larg
load
nucleoprotein
antigen
due
presenc
replic
viru
infect
tissu
would
suggest
competit
elisa
format
base
upon
np
target
antigen
might
provid
fig
competit
elisa
measur
bind
murin
mab
highli
purifi
sarscov
presenc
human
patient
serum
dilut
indic
normal
human
serum
control
white
bar
serum
convalesc
sar
patient
appli
well
coat
highli
purifi
whole
sarscov
mab
spike
specif
black
bar
nucleoprotein
specif
grey
bar
ad
reaction
result
depict
pool
normal
human
serum
nh
repres
mean
three
replic
test
perform
presenc
mab
combin
three
replic
test
perform
presenc
mab
result
repres
ident
assay
perform
duplic
gammairradi
patient
sera
mrad
p
p
student
ttest
increas
sensit
earli
detect
infect
toward
goal
abil
sar
convalesc
serum
compet
bind
mab
nucleoprotein
spike
whole
sarscov
test
via
elisa
serum
sampl
gammairrradi
prior
use
antibodi
serum
patient
clearli
inhibit
bind
nucleoprotein
mab
spike
protein
specif
mab
fig
contrast
antibodi
pool
normal
human
sera
compet
bind
either
mab
statist
analysi
data
show
mab
use
develop
serolog
competit
assay
subject
valid
test
sera
sever
sarscov
infect
patient
demonstr
similar
abil
inhibit
bind
nucleoprotein
specif
mab
spike
specif
mab
howev
sampl
inhibit
bind
nucleoprotein
without
inhibit
mab
spike
protein
suggest
spike
antibodi
respons
take
longer
develop
infect
human
data
shown
predomin
mab
spike
protein
mice
immunis
intact
viral
particl
led
us
test
biolog
activ
viru
neutralis
assay
sarscov
spike
protein
target
neutralis
antibodi
neutralis
posit
mab
bind
linear
epitop
spike
protein
unknown
conform
epitop
either
spike
protein
protein
total
six
mab
identifi
could
neutralis
sarscov
infect
tabl
significantli
two
mab
posit
identifi
specif
spike
determin
western
immunoblot
specif
target
remain
neutralis
mab
remain
elucid
crossneutralis
observ
anim
coronaviru
tgev
show
mab
specif
sarscov
epitop
crossneutralis
via
tgev
epitop
remain
mab
unabl
prevent
viral
growth
appli
neutralis
assay
data
suggest
vaccin
capabl
engend
neutralis
antibodi
respons
spike
protein
may
effect
block
infect
sarscov
four
western
immunoblot
neg
virusneutralis
mab
test
abil
bind
nativ
sarscov
infect
cell
immunofluoresc
assay
nonneutralis
mab
use
posit
control
sinc
mab
recognis
spike
protein
immunohistochem
stain
infect
vero
cell
data
shown
immunofluoresc
analysi
reveal
neutralis
mab
specif
recognis
sarscov
infect
uninfect
vero
cell
fig
irrelev
isotyp
match
mab
produc
ident
fashion
react
sarscov
infect
vero
cell
sarsneutralis
mab
bind
epitop
higher
conform
requir
nonneutralis
mab
less
toler
denatur
epitop
method
antigen
prepar
qualiti
antigen
greatli
affect
interpret
mab
bind
result
obtain
immunodotblot
assay
importantli
none
mab
react
mockinfect
lysat
assay
immunodotblot
data
shown
observ
suggest
major
neutralis
mab
like
target
surfac
expos
protein
epitop
nativ
viral
particl
one
put
protect
antigen
identifi
spike
protein
western
immunoblot
analysi
neutralis
mab
antigen
qualiti
conform
affect
bind
antisarscov
mab
elisa
purifi
viru
clearli
optim
antigen
test
seri
experi
lower
qualiti
sarscovinfect
vero
cell
lysat
howev
much
easier
prepar
diagnost
assay
therefor
limit
mab
bind
sarscov
infect
vero
cell
lysat
examin
via
elisa
major
mab
exhibit
decreas
bind
antigen
heat
denatur
tabl
heat
denatur
littl
effect
bind
nonneutralis
mab
also
maintain
high
level
bind
elisa
use
infect
vero
cell
lysat
howev
show
higher
background
irrelev
antigen
bsa
inconsist
reactiv
western
immunoblot
heat
denatur
viral
lysat
fig
tabl
combin
lower
qualiti
antigen
infect
vero
cell
lysat
along
heat
denatur
antigen
stronger
neg
effect
bind
neutralis
mab
compar
nonneutralis
mab
tabl
inde
regardless
western
immunoblot
reactiv
nonneutralis
clone
retain
greater
abil
bind
heat
denatur
antigen
compar
neutralis
mab
lower
mean
percent
reduct
od
per
group
p
student
ttest
tabl
support
earlier
observ
elisa
purifi
sarscov
fig
show
neutralis
mab
higher
requir
nativ
epitop
conform
compar
nonneutralis
mab
higher
conform
requir
neutralis
mab
may
help
explain
discrep
observ
immunodotblot
method
immunodotblot
overal
less
sensit
method
result
difficult
quantifi
compar
elisa
exampl
mab
bind
sarscov
spike
protein
western
immunoblot
neutralis
sarscov
infect
vitro
bind
western
immunoblot
gener
suggest
epitop
linear
natur
nonetheless
heat
treatment
clearli
affect
bind
mab
whole
virion
immunodotblot
data
reveal
lower
qualiti
antigen
infect
vero
cell
lysat
condit
heatplu
deterg
heatplu
deterg
reduc
agent
mab
bind
tabl
paper
describ
develop
murin
mab
recognis
sarscov
antigen
elisa
immunodotblot
western
immunoblot
surfac
infect
cell
neutralis
assay
data
consist
appear
coronaviru
antigen
surfac
infect
cell
replic
talbot
et
al
although
fixat
process
may
allow
reactiv
mab
intern
antigen
well
conform
sensit
sarscov
neutralis
mab
consist
properti
neutralis
mab
rais
envelop
virus
gener
requir
nativ
conform
bind
wilson
et
al
zwick
et
al
immunodotblot
assay
contradict
classif
sever
put
epitop
linear
suggest
posit
western
immunoblot
reaction
exampl
neutralis
mab
inde
appear
strict
tradit
classif
epitop
linear
conform
must
account
broader
spectrum
conform
requir
especi
deal
antigen
variabl
qualiti
differ
immunolog
test
howev
gener
neutralis
mab
consid
higher
requir
correct
epitop
conform
compar
nonneutralis
mab
elisa
import
verifi
optimis
condit
opstelten
et
al
use
viral
lysat
design
maxim
recoveri
coronaviru
protein
end
product
high
qualiti
recombin
protein
antigen
provid
use
insight
unfortun
prepar
highli
purifi
viral
antigen
requir
enorm
effort
biocontain
condit
emphasis
need
qualiti
recombin
antigen
assay
collect
data
demonstr
develop
mabbas
diagnost
tool
detect
sarscov
infect
well
within
reach
spike
protein
sarscov
target
neutralis
mab
epitop
spike
protein
provid
neutralis
target
sarscov
vitro
consist
spike
target
neutralis
antibodi
coronaviru
strain
godet
et
al
moreov
mab
may
use
identif
protect
epitop
vaccin
formul
enjuan
et
al
studi
underway
determin
ident
antigen
recognis
neutralis
western
immunnoblot
neg
mab
preliminari
analysi
nucleotid
predict
amino
acid
sequenc
clone
v
h
v
l
code
region
mab
suggest
mab
distinct
observ
impli
hybridoma
clone
express
antisarscov
neutralis
mab
deriv
individu
rearrang
clonal
select
b
cell
vivo
also
reveal
appar
consensu
sequenc
within
complementar
determin
region
requir
mab
exhibit
viru
neutralis
activ
find
make
feasibl
engin
multipl
mab
high
specif
avid
variou
sarscov
epitop
prepar
defin
cocktail
therapeut
mab
detail
descript
immunogenet
properti
mab
prepar
berri
et
al
manuscript
prepar
np
specif
mab
use
competit
elisa
patient
sera
import
earli
detect
sar
infect
key
risk
manag
diseas
first
descript
neutralis
mab
host
immunis
whole
sarscov
antibodi
prove
use
develop
new
diagnost
test
studi
antigen
variat
vaccin
develop
global
fight
sar
